Annual Report

Overview

The report covers Lepu Biopharma and its controlling subsidiaries for 2023, highlighting revenue of RMB225.4 million and a sharp reduction in losses to RMB30.3 million. It describes the global exclusive CMG901 licensing agreement with AstraZeneca and progress across its ADC and immuno-oncology pipeline. ESG governance is led by the Board with Audit Committee support, while the company reports 14,461.35 MWh comprehensive energy consumption and 6,139.96 metric tons of GHG emissions. Social disclosures cover 429 employees, 100% waste recycling, and zero work-related fatalities during the reporting period.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 25 April 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services